Tag:
Lexicon Pharmaceuticals
Latest Headlines
Latest Headlines
Lexicon shares shoot up on positive oral diabetes drug data
Shares of Lexicon Pharmaceuticals ( $LXRX ) shot up this morning after the developer touted positive signs of efficacy from its mid-stage study of its new oral diabetes drug. A double dose of the drug
Lexicon arthritis drug torpedoed by placebo response
Lexicon Pharmaceuticals ( $LXRX ) says its experimental arthritis drug was torpedoed by an unusually high placebo response in a mid-stage study, sending its stock tumbling 14 percent on the news. After
Promising diabetes data spur Lexicon shares
Shares of Lexicon Pharmaceuticals (LXRX) jumped 24 percent this morning after the developer reported promising signs that its type 2 diabetes drug lowered blood glucose levels in a mid-stage trial.
Lexicon restructures, cuts 102 employees--again
Lexicon Pharmaceuticals announced a new restructuring plan Thursday, which includes a 22 percent reduction in its workforce. The 102 positions cut will be primarily in basic research, early-stage
Lexicon cuts staff, focuses on R&D
Lexicon is reorganizing and cutting staff as it pursues its aggressive strategy to build its pipeline. The cuts will allow Lexicon to devote its resources to its strategic, business, and clinical
Invus invests $550M in Lexicon
New York-based investment firm Invus is purchasing up to $550 million in Lexicon Pharmaceuticals common stock to help finance Lexicon's 10 to 10 program. The 10 to 10 program is an ongoing company
SPOTLIGHT: Lexicon gains $20M in milestones
Lexicon Genetics has received two milestone payments totaling $20 million from Genentech for their collaboration on drug development. The payments cover their work in proteins and antibodies. Report
